Nikhil C. Munshi, MD
Adjunct Associate Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University




Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

VA Boston Healthcare System






Title
Integrative Oncogenomics of Multiple Myeloma
SPORE in Multiple Myeloma
Molecular Manipulation to Enhance Anti-Myeloma Response


Yr Title Project-Sub Proj Pubs
2021 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-08 40
2021 SPORE in Multiple Myeloma 5P50CA100707-18 422
2021 Tissue Banking Core 5P50CA100707-18-8564 422
2021 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-18-8567 422
2020 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-07 40
2020 Integrative Oncogenomics of Multiple Myeloma 5P01CA155258-09 229
2020 Core 1: Administrative and Communication Core 5P01CA155258-09-5939 229
2020 Project 4. Targeting genomic instability and evolution in myeloma 5P01CA155258-09-5947 229
2020 SPORE in Multiple Myeloma 5P50CA100707-17 422
2020 Tissue Banking Core 5P50CA100707-17-8564 422
Showing 10 of 82 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, Garrido V, Rufian L, Sanchez R, Aguilar-Garrido P, Barrio S, Martín MA, Bolli N, Tai YT, Szalat R, Fulciniti M, Munshi N, Martínez-López J, Linares M, Gallardo M. Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers (Basel). 2021 Jun 25; 13(13). PMID: 34202390; PMCID: PMC8268477; DOI: 10.3390/cancers13133189;
     
  2. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jun 24. PMID: 34175021
     
  3. Sarosiek S, Varga C, Jacob A, Fulciniti MT, Munshi N, Sanchorawala V. Detection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer J. 2021 Jun 21; 11(6):117.View Related Profiles. PMID: 34155198; PMCID: PMC8217177; DOI: 10.1038/s41408-021-00511-6;
     
  4. Ludwig H, San-Miguel J, Munshi N, Sonneveld P, Mateos MV, Moreau P, Terpos E. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. Am J Hematol. 2021 08 01; 96(8):896-900. PMID: 34057243; PMCID: PMC8212086; DOI: 10.1002/ajh.26263;
     
  5. DuMontier C, Fillmore NR, Yildirim C, Cheng D, La J, Orkaby AR, Charest B, Cirstea D, Yellapragada S, Gaziano JM, Do N, Brophy MT, Kim DH, Munshi NC, Driver JA. Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. Cancers (Basel). 2021 Jun 18; 13(12).View Related Profiles. PMID: 34207459; PMCID: PMC8233717; DOI: 10.3390/cancers13123053;
     
  6. Munshi NC, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed Myeloma. Reply. N Engl J Med. 2021 06 17; 384(24):2357-2358. PMID: 34133871
     
  7. Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos M, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid KE, Castillo J, Munshi NC, Anderson KC, Cameron M, Buhrlage S, Gray NSS, Treon SPP. The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 Jun 16.View Related Profiles. PMID: 34132782
     
  8. Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur MK, Sewastianik T, Ogiya D, An G, Gao S, Yang L, Ji T, Bianchi G, Wen K, Tai YT, Munshi N, Richardson P, Carrasco R, Cang Y, Anderson KC. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun; 7(23). PMID: 34088671; PMCID: PMC8177702; DOI: 10.1126/sciadv.abg2697;
     
  9. Fillmore NR, La J, Szalat RE, Tuck DP, Nguyen V, Yildirim C, Do NV, Brophy MT, Munshi NC. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2021 06 01; 113(6):691-698.View Related Profiles. PMID: 33031532; PMCID: PMC7665587; DOI: 10.1093/jnci/djaa159;
     
  10. Kumar S, Buon L, Talluri S, Roncador M, Liao C, Zhao J, Shi J, Chakraborty C, Gonzalez G, Tai YT, Prabhala R, Samur MK, Munshi NC, Shammas MA. Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. Commun Biol. 2021 May 24; 4(1):617. PMID: 34031527; PMCID: PMC8144613; DOI: 10.1038/s42003-021-02125-x;
     
Showing 10 of 506 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 506 publications over 27 distinct years, with a maximum of 29 publications in 2015 and 2018

YearPublications
19931
19961
19975
19987
199913
20006
200114
200226
200325
200416
200516
200619
200720
200820
200926
201021
201125
201222
201328
201425
201529
201623
201727
201829
201920
202022
202120

Contact for Mentoring:

Munshi's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department